RYZ101

Small molecule

RRayzeBio, Inc.

RYZ101 is one of 17 small molecule programs targeting Breast Cancer. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Breast CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Gemzar

GGynecologic Oncology Group

Preclinical

22 3

Adenocard

Astellas

Preclinical

1 4

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 6

Acupan

YYonsei University

Preclinical

1 7

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 8

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

3 9

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 10

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Recruiting

GEP-NET

NCT05477576

Q1 2029

Phase 1Recruiting

ES-SCLC

NCT05595460

Q1 2033

Phase 1/2Active, not recruiting

Breast Cancer

NCT06590857

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Active, not recruiting·RRayzeBio, Inc.·Phase 1/2·NCT06590857·16 enrolled

GEP-NET1 trial

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting·RRayzeBio, Inc.·Phase 3·NCT05477576·288 enrolled

ES-SCLC1 trial

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

Recruiting·RRayzeBio, Inc.·Phase 1·NCT05595460·49 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for RYZ101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RYZ101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RYZ101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — RayzeBio, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: RRayzeBio, Inc.

RYZ101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q1 2029

Q1 2033

Trials by Indication[1]

Breast Cancer1 trial

GEP-NET1 trial

ES-SCLC1 trial

References

Drug Info

Quick Facts

Related News